cropper

The Silver Surfer
Senior Citizens Surfing the Internet

  • Home
  • Categories
    • Health & Wellness
    • Money & Legal
    • Housing & Living
    • Lifestyle & Leisure
    • Technology for Seniors
    • Local Resources
July 29.2025
2 Minutes Read

Medial Opening Wedge High Tibial Osteotomy: A Potential Game Changer for Knee OA

Illustrated knee joint showing inflammation for medial opening wedge high tibial osteotomy.

Understanding Medial Opening Wedge High Tibial Osteotomy

Medial opening wedge high tibial osteotomy (HTO) is a surgical procedure primarily used to treat knee osteoarthritis (OA) in patients who are not suitable candidates for knee replacement surgery. This innovative approach aims to realign the knee joint by reshaping the tibia, allowing for better distribution of body weight across the joint. As a result, it can help in preserving cartilage and improving overall joint function. Recent findings from a Canadian study indicate a promising path forward for individuals with medial compartment OA, highlighting that surgery might offer tangible benefits over traditional nonsurgical treatments.

What the Study Revealed: A Closer Look

This study, which followed patients for two years, revealed compelling results. Patients who underwent HTO experienced a mean 2% decline in cartilage thickness — a stark contrast to the 9% decline seen in those receiving usual care. Furthermore, the Knee Injury and Osteoarthritis Outcome Score (KOOS) results showed that HTO patients enjoyed an average improvement of about 25 points compared to a meager 9 points for the usual care group. This marks a clear indication that HTO can not only preserve cartilage but also significantly enhance the quality of life for knee OA patients.

Whom is HTO Right For?

While the advantages of HTO are notable, it’s essential to understand that this surgery is not a one-size-fits-all solution. This treatment is specifically geared towards patients suffering from medial compartment OA and varus alignment (often described as bowleggedness). For those with more advanced OA or those who experience severe joint pain and disability, total knee replacement remains a viable option. However, HTO provides an alternative for younger and active individuals who seek to delay or avoid the need for a complete joint replacement.

The Journey of Recovery After Surgery

Recovery from medial opening wedge high tibial osteotomy typically requires about six months before patients can return to their normal activities. The success of individual recovery can be bolstered by a comprehensive nonsurgical care plan that may include physical therapy, diet adjustments, and guided exercise. Such holistic care not only supports the surgical results but also helps reinforce a healthier lifestyle post-recovery.

Conclusion: A Step Towards Healthier Knees

For those enduring the challenges of knee osteoarthritis, particularly younger patients, medial opening wedge high tibial osteotomy presents a beacon of hope. With its potential to effectively preserve cartilage and enhance functional outcomes, it offers an enticing alternative to traditional treatments. As ongoing research continues to shed light on its long-term effectiveness, HTO may become a cornerstone in knee OA management. If you're considering options for knee treatment, it's worth discussing this innovative procedure with a healthcare professional.

Health & Wellness

30 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.19.2026

Breakthrough Insights: Diranersen Therapy Shows Benefits for Alzheimer's Patients Over Two Years

Update Understanding Tau Therapy's Promising Benefits for Alzheimer's Patients In a remarkable breakthrough for Alzheimer's research, diranersen, an investigational medication, continues to show significant benefits in slowing the decline of cognitive abilities. Recent findings from a two-year study confirm that this therapy works by targeting tau protein, a key factor in the progression of Alzheimer's disease. Presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, Dr. Lawren VandeVrede from the University of California San Francisco highlighted that over 96 weeks, diranersen led to a meaningful recovery in cognitive functions. How Diranersen Works and Its Impact on Cognitive Decline Diranersen is an antisense oligonucleotide therapy that aims to reduce tau levels, which can collect in the brain and contribute to the disease's progression. The results showed a 1.09-point improvement in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score among participants who received a 60-mg dose twice a year. This dosage displayed the most significant results, proving invaluable since a one-point change in CDR-SB is considered clinically meaningful. A Closer Look at the Study and Its Findings The CELIA trial enrolled 416 participants with mild cognitive impairment from Alzheimer's disease and tested different doses of diranersen. Interestingly, while various dosages were evaluated, the lower 60-mg dose performed the best, leading to a 38% improvement in cognitive measures between 76 and 96 weeks. As the findings continue to evolve, researchers are optimistic about this therapy's potential to enhance cognitive function for a longer duration, which could mean new hope for patients struggling with this debilitating disease. Safety and Future Implications of Diranersen While the results are promising, it is important to consider the safety profile. During the study, adverse events were common but mostly mild, such as headaches and post-lumbar puncture syndrome. These findings continuously reassure researchers about the therapy's tolerability. Experts emphasize that diranersen's ability to lower tau without affecting amyloid protein makes it particularly exciting. This presents a potential strategy in combined therapies that target multiple aspects of Alzheimer's, aiming for a more comprehensive approach to treatment. Looking Ahead: The Future of Alzheimer's Treatments The upcoming phase III trials will be crucial in confirming the effectiveness and safety of diranersen on a larger scale. As Laura Nisenbaum, interim chief science officer of the Alzheimer's Drug Discovery Foundation, points out, understanding how tau therapy can work alongside traditional anti-amyloid treatments could be groundbreaking in the fight against Alzheimer's disease. As Alzheimer's affects millions, continued research like this offers hope and insight into managing and potentially reversing symptoms. Stay informed about these developments as they may mark a new era in Alzheimer's treatment that could benefit not just today’s patients but future generations.

11.18.2026

Why High Cardiac Troponin I Readings Alone Aren't Enough

Update Understanding Cardiac Troponins: The Basics Cardiac troponins, particularly troponin I (cTnI), are essential blood markers that help doctors understand heart health. These proteins are released when the heart is damaged, and measuring their levels can help indicate the risk of cardiovascular problems. However, recent research warns that simply looking at cTnI levels might not give the whole picture. What Are Macrotroponins and Why Do They Matter? Macrotroponins are complex molecules formed from autoantibodies attaching to troponin. They are much larger than regular troponins and can linger in the bloodstream longer, making tests show heightened cTnI levels. In simple terms, while doctors often look at high cTnI levels to assess heart health, they must also consider if these high levels are due to macrotroponins. New Findings from Norway: A Wake-Up Call In a significant study from Norway involving over 3,700 community members, researchers discovered some surprising truths. Those with high cTnI readings and no macrotroponins faced a staggering 50% chance of developing cardiovascular problems over 8.3 years. In contrast, those with high cTnI but also possessing macrotroponins had a much lower incident rate of just 6.8%. Why Misclassifying Risks Can Be Dangerous This misclassification could lead to critical oversights in patient care. High cTnI readings can indicate severe risk, but if macrotroponins are present, the actual risk may be much lower. Thus, it’s imperative for physicians to consider both cTnI levels and the presence of macrotroponins to make informed medical decisions. The Need for Enhanced Diagnostic Practices The study emphasizes that by recognizing the influence of macrotroponins, healthcare providers can improve their assessments of cardiac risk. This means creating fresh guidelines that factor in both troponin levels and macrotroponin presence could be monumental in shaping more accurate health responses. Final Thoughts: What This Means for Patients For those monitoring heart health, these insights are crucial. Patients should be aware that high cTnI does not automatically signal danger, especially if macrotroponins are present. Engaging in discussions with healthcare providers about testing methods and what results actually indicate can empower patients to better understand their cardiovascular risks.

11.17.2026

The Hidden Dangers of Agent Orange: Linking Exposure to Parkinson's Disease

Update Understanding the Link Between Agent Orange and Parkinson’s Disease Recent research has unveiled significant findings regarding the health risks faced by Vietnam-era military veterans exposed to Agent Orange, a potent herbicide used during the Vietnam War. A study of over 4 million Veterans Affairs (VA) health records has established that these veterans are at a 57% higher risk of developing Parkinson's disease and other neurodegenerative disorders. This alarming statistic indicates that veterans were not just courageous soldiers but also faced long-term health consequences from their service. What Is Agent Orange? Agent Orange was a toxic herbicide extensively utilized by the U.S. military to clear vegetation and expose enemy positions. This chemical was not just an ordinary weedkiller; it was a mixture containing 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), along with TCDD, a highly toxic dioxin. Despite the phasing out of 2,4,5-T in the 1970s, the use of 2,4-D remains prevalent today across various sectors, including agriculture and landscaping, which raises critical public health questions. Health Impacts of Agent Orange on Veterans The study led by Dr. Gregory Scott and his team highlights that veterans who handled Agent Orange directly had even higher chances—up to twice as likely—of developing Parkinson’s disease and related conditions, including REM sleep behavior disorder. This reinforces the long-held suspicions of healthcare providers and the veterans themselves regarding the link between Agent Orange exposure and neurodegenerative diseases. Broader Implications Beyond Veterans Time and again, evidence suggests that the toxic effects of Agent Orange are not limited to veterans alone. People living near agricultural areas where 2,4-D is used—like farmers and groundskeepers—face similar risks. Notably, recent studies revealed that living close to golf courses is associated with a 126% increased risk of Parkinson's disease, illustrating how widespread this issue is beyond military circles. Why Does This Matter Now? As we continue to learn about the long-term consequences of Agent Orange exposure, it becomes increasingly clear that proactive measures should be taken to prevent future exposures to harmful herbicides and pesticides. Dr. Scott emphasizes the need for immediate action to comprehend and address the health risks associated with newer herbicides before they become entrenched in our understanding, just as Agent Orange was for veterans. Conclusion: A Call for Awareness The findings of this recent study are a wake-up call for not only veterans but for communities across the U.S. As the knowledge of dangerous chemicals continues to evolve, so too must our efforts to protect public health. Advocacy for research into environmental health effects and vigilant monitoring of agricultural chemicals are imperative to safeguard both current and future generations. Understanding these risks can lead to stronger policies protecting veterans and civilians alike.

Silver Surfer Media

A division of

Electronic Commerce Engineering Corporation

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

+19085200096

AVAILABLE FROM 9AM - 5PM

Monday ~ Friday

Green Township, New Jersey

 07860-5406

ABOUT US

The Sussex County Advisor is operated by synergetic.media a subsidiary of  Electronic Commerce Engineering Corporation, Green Township, NJ 07860-5406

© 2026 Electronic Commerce Engineering Corporation All Rights Reserved. 16 Wintermute Rd, Green Township, NJ 07860-5406 . Contact Us . Terms of Service . Privacy Policy

{"company":"Electronic Commerce Engineering Corporation","address":"16 Wintermute Rd","city":"Green Township","state":"NJ","zip":"07860-5406","email":"info@ecommerceengineering.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*